Changwen Xue
YOU?
Author Swipe
View article: Long-term outcome of using Ara-C or not in children’s APL
Long-term outcome of using Ara-C or not in children’s APL Open
The use of cytarabine (Ara-C) in treating acute promyelocytic leukemia (APL) is controversial. This study was conducted to demonstrate the effect of treatment with or without Ara-C on long-term event-free survival (EFS) or overall survival…
View article: Infusion of 14 days Blinatumomab in Combination with Chemotherapy for 46-day MRD+ Pediatric B-ALL Patients in Intermediate/High-Risk Group Results in MRD Conversion and BiTE Induced Immune Response to Malignant Cells
Infusion of 14 days Blinatumomab in Combination with Chemotherapy for 46-day MRD+ Pediatric B-ALL Patients in Intermediate/High-Risk Group Results in MRD Conversion and BiTE Induced Immune Response to Malignant Cells Open
The conventional intensity of chemotherapy has reached its limit. Despite the efficacy of blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL) adults with measurable residual disease (MRD) has been proved, studies in children with M…
View article: PB2691: ARSENIC RETENTION IN TISSUES AND QUALITY OF LIFE IN PEDIATRIC ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENICALS: A CROSS SECTIONAL STUDY
PB2691: ARSENIC RETENTION IN TISSUES AND QUALITY OF LIFE IN PEDIATRIC ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENICALS: A CROSS SECTIONAL STUDY Open
Topic: 35. Quality of life and palliative care Background: Acute promyelocytic leukemia (APL) is characterized by the formation of a PML-RARa fusion gene and almost curable disease with the use of all-trans retinoic acid (ATRA) and arsenic…
View article: P1402: INFUSION OF 14 DAYS BLINATUNOMAB IN COMBINATION WITH CHEMOTHERAPY FOR 46-DAY MRD+ PEDIATRIC B-ALL PATIENTS IN INTERMEDIATE/HIGH-RISK GROUP RESULTS IN MRD CONVERSION.
P1402: INFUSION OF 14 DAYS BLINATUNOMAB IN COMBINATION WITH CHEMOTHERAPY FOR 46-DAY MRD+ PEDIATRIC B-ALL PATIENTS IN INTERMEDIATE/HIGH-RISK GROUP RESULTS IN MRD CONVERSION. Open
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Despite the efficacy of blinatunomab (blin) in adults with measurable residual disease (MRD) has been proved [Gökbuget, Blood 2018], studies in children…